Axsome Therapeutics, Inc. (AXSM)
206.68
-1.67
(-0.80%)
USD |
NASDAQ |
Sep 04, 16:00
206.96
+0.28
(+0.14%)
After-Hours: 20:00
Axsome Therapeutics Research and Development Expense (Quarterly) : 46.08M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 46.08M |
| March 31, 2026 | 52.56M |
| December 31, 2025 | 48.68M |
| September 30, 2025 | 40.04M |
| June 30, 2025 | 49.54M |
| March 31, 2025 | 44.22M |
| December 31, 2024 | 54.88M |
| September 30, 2024 | 44.93M |
| June 30, 2024 | 49.59M |
| March 31, 2024 | 36.59M |
| December 31, 2023 | 30.67M |
| September 30, 2023 | 28.63M |
| June 30, 2023 | 20.48M |
| March 31, 2023 | 17.70M |
| December 31, 2022 | 14.61M |
| September 30, 2022 | 14.80M |
| June 30, 2022 | 15.72M |
| March 31, 2022 | 12.55M |
| December 31, 2021 | 13.75M |
| September 30, 2021 | 13.15M |
| June 30, 2021 | 14.49M |
| March 31, 2021 | 16.59M |
| Date | Value |
|---|---|
| December 31, 2020 | 17.38M |
| September 30, 2020 | 14.79M |
| June 30, 2020 | 10.54M |
| March 31, 2020 | 27.52M |
| December 31, 2019 | 19.20M |
| September 30, 2019 | 15.84M |
| June 30, 2019 | 11.00M |
| March 31, 2019 | 7.603M |
| December 31, 2018 | 7.151M |
| September 30, 2018 | 6.041M |
| June 30, 2018 | 5.550M |
| March 31, 2018 | 4.752M |
| December 31, 2017 | 4.494M |
| September 30, 2017 | 4.471M |
| June 30, 2017 | 5.007M |
| March 31, 2017 | 5.985M |
| December 31, 2016 | 5.807M |
| September 30, 2016 | 5.569M |
| June 30, 2016 | 5.298M |
| March 31, 2016 | 4.526M |
| December 31, 2015 | 2.208M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.819B |
| Liquidia Corp. | 16.88M |
| Filana Therapeutics, Inc. | 3.303M |
| CorMedix, Inc. | 6.684M |
| Eloxx Pharmaceuticals, Inc. | 2.84M |